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Background: Constitutional factors such as age, sex and height, and acquired factors such as
atopy and smoking, influence exhaled nitric oxide (FENO) levels. The utility of predicted values
based on reference equations which account for these factors has not been evaluated.
Aim: To compare the performance characteristics of absolute versus % predicted values for
FENO as predictors of diagnosed asthma and steroid response.
Methods: We compared the sensitivities, specificities and likelihood ratios using FENO (% pre-
dicted) with absolute values for FENO (ppb) in 52 steroid-naive subjects with non-specific respi-
ratory symptoms. The reference equations of Olin et al. (Chest, 2007) and Dressel et al. (Resp.
Med., 2008) were used to derive predicted values. Receiver operating curve analyses were per-
formed and the areas under the curve (AUC) were calculated for two outcomes: diagnosed
asthma (yes/no), and steroid response after fluticasone for 4 weeks (defined as 12% increase
in FEV1; increase in mean morning PEF 15%; reduction in symptoms 1 point; increase in
PC20AMP of 2 doubling doses).
Results: The AUCs for diagnosed asthma were: FENO (absolute) 0.770; FENO (% pred.): 0.758
(Olin) and 0.775 (Dressel) (NS). The AUCs for FENO (abs.) and FENO (% pred.) with respect to
the four indices of steroid response were likewise not significantly different.
Conclusion: Correcting FENO for combinations of age, sex, height, smoking and atopy using
reference equations did not enhance the performance characteristics of FENO as a predictor
of either the diagnosis of asthma or steroid responsiveness in patients with chronic airways-
related symptoms.
ª 2011 Elsevier Ltd. All rights reserved.474 0999x8785; fax: þ64 3 474 6246.
bow.otago.ac.nz (D. Robin Taylor).
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Measuring the fraction of nitric oxide in exhaled air (FENO)
is increasingly used in the assessment of airway inflamma-
tion, notably asthma.1 Diagnostically, single measurements
shed light on the aetiology of chronic non-specific respira-
tory symptoms. In particular, high values suggest, and low
values usually preclude, the possibility that underlying
airway inflammation will be steroid responsive.2 In the
monitoring of complex asthma, repeated measurements
help the clinician to determine whether uncontrolled
airway inflammation or other factors are the reason for
persisting asthma-like symptoms, and this information is
useful in guiding therapy.3
Airway NO levels are dependent on both constitutive and
inducible nitric oxide synthase enzyme activity.4 Based on
a study in twins, Lund et al. have reported that approxi-
mately 60% of the variability in exhaled NO levels is
explained by genetic factors.5 Epidemiologically, constitu-
tional factors such as age, sex and height, and acquired
factors such as atopy and smoking status, combine to
influence NO levels even in otherwise healthy individuals.1
Thereafter, in patients with airways symptoms, the signal
which is attributable to pathological airway inflammation is
superimposed.
To date, FENO measurements have been reported as
absolute values, and pooled results from various patient
groups have been used to establish relevant cut-points for
clinical interpretation. Background factors known to influ-
ence FENO have not been taken into account. Hitherto, the
utility of predicted values based on reference equations has
not been evaluated. In the present study, we aimed to
address this question using data from a previously published
study designed to investigate the performance character-
istics of FENO in the diagnosis of asthma and the assessment
of steroid responsiveness.2 We compared the sensitivities,
specificities, and positive and negative likelihood ratios
using predicted values for FENO with those obtained using
absolute values.MethodsPatients and baseline assessments
Data for the present analysis were obtained from a study
which has been reported previously.2 Briefly, 52 steroid-
naı¨ve patients presenting to their primary care doctor with
new, undiagnosed symptoms of cough, wheeze, or dysp-
noea of 6 weeks duration or longer were studied. Baseline
assessment included: spirometry and response to broncho-
dilator, serial twice daily peak flow measurements over 7
days, a methacholine bronchial challenge test, and a FENO
measurement. Thereafter, patients underwent a single-
blind, placebo-controlled, cross-over trial of inhaled fluti-
casone 250 mg b.i.d. for four weeks per treatment arm. As
well as obtaining twice daily diary data of symptoms and
peak flows, patients also underwent spirometry and bron-
chial challenge testing with adenosine monophosphate
(AMP) before and after each of the two treatment arms.Criteria for diagnosis of asthma and steroid
responsiveness
The criteria for diagnosing asthma were typical symptoms
and, at baseline, either a positive response to bronchodi-
lator, defined as an increase in forced expiratory volume in
1 s (FEV1) 15 min after inhaled albuterol of 12% and/or
a positive methacholine challenge, defined as a provocative
dose of methacholine resulting in a 20% reduction in FEV1 of
<8 mmol (PD20). “Steroid response” was determined cate-
gorically (yes/no) using each of four study end-points:
improvement in FEV1 (12%); improvement in mean
morning peak flow (15%); reduction in composite symp-
toms score (1 point); improvement in PC20AMP (provoca-
tive concentration of AMP resulting in a 20% reduction in
FEV1) of 2 doubling doses.Measurements
FENO was measured before any spirometric manoeuvres
using a chemiluminescence analyser (NiOX; Aerocrine,
Solna, Sweden) at an exhalation flow rate of 50 mL/s,
according to current guidelines.6 The response to adenosine
was measured using a standard protocol.7Analyses
In the present study, the accuracy of baseline FENO as an
absolute value (FENO abs, ppb) and expressed as % pre-
dicted values (FENO % pred.) as “predictors” of the
response to treatment with inhaled fluticasone was calcu-
lated using receiver operating characteristic (ROC) curve
analyses. Two FENO % pred. values were calculated for each
patient using reference equations from Olin et al.8 and
Dressel et al.9 In the first of these, age, height and atopic
status were used as explanatory factors: log (n)
FENOZ 0.00082 þ 0.21 (if atopyZ yes) þ 0.013  height
(cm) þ 0.01  age(years). In the second, sex, height, atopy,
and smoking status were used: FENO Z 17.49  1.49 [if
atopyZ yes]  0.627 [if smokingZ yes]  1.235 [if current
infection Z yes]  1.174 [if sex Z male]  1.113(height in
cm170)/10.
For each of the three FENO variables, the sensitivity,
specificity, positive and negative predictive values and
likelihood ratios over a range of cut-points were calculated
with respect to: i) the diagnosis of asthma at presentation
(yes/no); and ii) steroid response (yes/no; four categories
using the criteria outlined above). Atopy was defined as
having a wheal of >2 mm more than the negative control
to one or more allergens (cat, grass pollen, house dust
mite).Results
Data from a total of 52 patients were analysed. Only 3 were
current smokers, and 40 (77%) were atopic. The baseline
FENO levels ranged from 6.3 to 242.0 ppb, equivalent to
40.5e2102% predicted using the Olin equation, and
33e1414% predicted using the Dressel equation.
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of asthma
After initial study tests, 19 patients had asthma diagnosed
on the basis of one or both of the a priori criteria; 33 did
not have asthma. A further 8 patients who did not fulfil
criteria for a diagnosis of asthma at study entry were
subsequently diagnosed with asthma based on their
objective response to inhaled fluticasone. However, for the
purposes of this study, “diagnosed asthma at presentation”
was considered to be the more appropriate categorisation.
The optimum cut-points for diagnosing asthma were:
FENO (abs). 41.7 ppb, and FENO (% pred.) 297% (Olin) and
190% (Dressel). There was no significant difference in the
area under the curve for “asthma: yes/no” between FENO
(abs) and FENO (% pred.): 0.770 versus 0.758 (Olin) and
0.775 (Dressel) respectively. Thus no advantage could be
obtained from using predicted rather than absolute values
for FENO to support the diagnosis of asthma.
FENO (abs.) versus FENO (% pred.) as predictors of
steroid response
The areas under the receiver-operating curve for FENO
(abs.) and the two values for FENO (% pred.) with respect to
the four indices of steroid response are given in Table 1.
More detailed performance characteristics in relation to
increase in FEV1 and in PC20AMP with inhaled steroid are
given in Tables 2A and 2B. FENO (abs.) and both sets of
values for FENO (% pred.) were not significantly different in
their predictive performances. Results for the same
comparisons in relation to change in mean morning peak
flows (increase of 15%) and improvement in symptoms
(reduction of 1 point in composite score) are not reported
here in detail, but were not significantly different.
Further receiver-operating curveanalyseswereperformed
inwhichbaselineFENOwasexpressedas%of theupper limit of
the 95% confidence interval for the predicted value (Dressel
only) for each individual. This approach resulted in AUCs
which were in fact lower than those obtained using FENO %
predicted i.e. the performance characteristics were worse
using this approach (data not reported). A subgroup analysis
was performed in the small number ofpatients (nZ 13)whose
FENO was greater than the upper limit of the 95% confidenceTable 1 Areas under the receiver operating curve for FENO abs
Outcome measure before/after
trial of inhaled steroid
FENO (abs.)
AUC O
cu
Increase in FEV1 of 12% 0.763 9
Improvement in morning peak flow
over 7 days of 15%
0.812 11
Reduction in composite symptom score 1 point 0.643 16
Increase inPC20 AMP 2 doubling doses 0.912 4interval for predicted values (Dressel only). Again, this did not
yield improved performance characteristics.Discussion
The results of the present study indicate that correcting
FENO measurements for combinations of age, sex, height,
smoking history and atopic status using the reference
equations of Olin et al.8 or Dressel et al.9 did not enhance
the performance characteristics of FENO as a predictor of
either the diagnosis of asthma per se or of steroid respon-
siveness, in steroid-naı¨ve patients with persistent non-
specific respiratory symptoms. The areas under the ROC
curves (AUCs) with FENO absolute (ppb) were almost iden-
tical to the AUCs using FENO % predicted based on either of
the two reference equations. Given that there appeared to
be significant differences in the derived optimum cut-
points for FENO % predicted depending on whether the
equation by Olin or Dressel was used (see Table 1), it would
seem more appropriate to use FENO absolute (ppb).
Recently, reference values for FENO have been reported
in a number of studies. Obtaining such data was considered
important since so many biological factors other than airway
inflammation are known to influence FENO. As well as Olin
8
and Dressel,9 additional datasets have been published.10e12
Based on experience with other lung function tests, it is
almost intuitive to expect that age, sex, and height should
be included in reference equations. Although the evidence is
not consistent, there are data to suggest that these factors
are important determinants of FENO,
11,13e17. There is also
evidence that other “acquired” but commonly encountered
factors such as atopy18e20 and smoking,21,22 are relevant.
However, again, there is no consistent agreement as to
which factors ought to be routinely included in reference
equations. Perhaps this reflects the fact that individual
factors do not influence FENO to a great extent, and any one
is found to be significant in some but not all populations.
In the study by Olin et al.,8 only 11% of the variance in
FENO was explained by age, height and atopic status, the
variables which were included in these authors’ reference
equation. Similarly, in the study by Dressel et al.,9 even
although the number of factors e sex, height, atopy,
smoking status and recent respiratory infection e was
greater, they accounted for only 26% of the overallolute and FENO % predicted as predictors of steroid response.
FENO (% pred.)
using Olin equation
FENO (% pred.)
using Dressel
equation
ptimum
t-point (ppb)
AUC Optimum
cut-point
(% pred.)
AUC Optimum
cut-point
(% pred.)
0 0.760 389 0.794 272
5 0.798 892 0.814 204
0 0.660 892 0.643 488
7 0.900 311 0.908 195
Table 2A Sensitivities (Sens.), specificities (Spec.), positive and negative predictive values (PPV and NPV), and positive and negative likelihood ratios (LRþ and LR), for
different FENO cut-points (absolute and % predicted) as predictors for an increase in FEV1 of 12% or greater in 52 patients with
non-specific respiratory symptoms treated with inhaled fluticasone for 4 weeks. Cells with no numeric result are because in the
calculation of likelihood ratios, the denominator was 0.
FENO abs. (ppb) FENO (% predicted) using Olin equation FENO (% predicted) using Dressel equation
Cut point Sens. Spec. PPV NPV LRþ LR Cut point Sens. Spec. PPV NPV LRþ LR Cut point Sens. Spec. PPV NPV LRþ LR
25 83.3 57.5 37.0 92.0 1.96 0.29 80 100.0 17.5 26.7 100.0 1.21 0.00 80 83.3 52.5 34.5 91.3 1.75 0.32
40 75.0 70.0 42.9 90.3 2.50 0.36 100 91.7 25.0 26.8 90.9 1.22 0.33 100 83.3 60.0 38.5 92.3 2.08 0.28
50 58.3 80.0 46.7 86.5 2.92 0.52 120 91.7 42.5 32.4 94.4 1.59 0.20 120 83.3 65.0 41.7 92.9 2.38 0.26
70 41.7 87.5 50.0 83.3 3.33 0.67 150 83.3 55.0 35.7 91.7 1.85 0.30 150 75.0 70.0 42.9 90.3 2.50 0.36
90 41.7 92.5 62.5 84.1 5.56 0.63 200 75.0 67.5 40.9 90.0 2.31 0.37 200 66.7 82.5 53.3 89.2 3.81 0.40
110 25.0 95.0 60.0 80.9 5.00 0.79 300 58.3 77.5 43.8 86.1 2.59 0.54 300 41.7 92.5 62.5 84.1 5.56 0.63
130 16.7 95.0 50.0 79.2 3.33 0.88 500 41.7 85.0 45.5 82.9 2.78 0.69 500 8.3 97.5 50.0 78.0 3.33 0.94
150 16.7 95.0 50.0 79.2 3.33 0.88 1000 8.3 97.5 50.0 78.0 3.33 0.94 1000 0.0 97.5 0.0 76.5 0.0 1.03
Table 2B Sensitivities (Sens.), specificities (Spec.), positive and negative predictive values (PPV and NPV), and positive and negative likelihood ratios (LRþ and LR) for
different FENO cut-points (absolute and % predicted) as predictors for a reduction in airways responsiveness to AMP (increase in
PC20AMP of 2 doubling doses or greater) in 52 patients with non-specific respiratory symptoms treated with inhaled fluticasone for
4 weeks. The “e” value for LRþ indicates an undefined LRþ value due to a cell with value 0.
FENO abs. (ppb) FENO (% predicted) Using Olin equation FENO (% predicted) Using Dressel equation
Cut point Sens. Spec. PPV NPV LRþ LR Cut point Sens. Spec. PPV NPV LRþ LR Cut point Sens. Spec. PPV NPV LRþ LR
25 88.2 67.6 57.7 92.0 2.73 0.17 80 94.1 17.6 36.4 85.7 1.14 0.33 80 94.1 64.7 57.1 95.7 2.67 0.09
40 88.2 82.4 71.4 93.3 5.00 0.14 100 94.1 29.4 40.0 90.9 1.33 0.20 100 88.2 70.6 60.0 92.3 3.00 0.17
50 76.5 94.1 86.7 88.9 13.00 0.25 120 94.1 50.0 48.5 94.4 1.88 0.12 120 88.2 76.5 65.2 92.9 3.75 0.15
70 52.9 97.1 90.0 80.5 18.00 0.49 150 88.2 64.7 55.6 91.7 2.50 0.18 150 88.2 82.4 71.4 93.3 5.00 0.14
90 47.1 100.0 100.0 79.1 e 0.53 200 88.2 79.4 68.2 93.1 4.29 0.15 200 76.5 94.1 86.7 88.9 13.00 0.25
110 29.4 100.0 100.0 73.9 e 0.71 300 82.4 94.1 87.5 91.4 14.00 0.19 300 41.2 97.1 87.5 76.7 14.00 0.61
130 23.5 100.0 100.0 72.3 e 0.77 500 58.8 97.1 90.9 82.5 20.00 0.42 500 11.8 100.0 100.0 69.4 e 0.88
150 23.5 100.0 100.0 72.3 e 0.77 1000 11.8 100.0 100.0 69.4 e 0.88 1000 5.9 100.0 100.0 68.0 e 0.94
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Predicted versus absolute values for exhaled nitric oxide 1633variance. Thus converting FENO values from absolute (ppb)
to predicted values (%) using reference equations does not
improve the performance characteristics of FENO because
so little of the total variation in baseline FENO is due to the
factors included in the reference equations.
It might be argued that the selection criteria for study
enrolment and the small sample size limit the generaliz-
ability of the present results. However, the study pop-
ulation (and hence the pre-test probabilities) was
appropriate. The patients selected were from a primary
care setting and comprised a mixed group with hitherto
undiagnosed chronic non-specific respiratory symptoms.
Such patients are common, and are the ones in which
exhaled nitric oxide measurements may be helpful as
a diagnostic test. Secondly, the present study was a retro-
spective analysis based on new information about how FENO
measurements might be more appropriately used and
interpreted in relation to predicted values. In fact, in the
original study, designed to evaluate the performance of
FENO as a predictor of steroid responsiveness,
2 there were
highly significant differences in mean steroid response
between patients with high versus low FENO levels. AUCs
for FENO as a predictor were highly significantly different
from 0.5 (e.g. AUC Z 0.91 when FENO is used to predict
improvement in airway hyper-responsiveness with flutica-
sone). This means that numbers were sufficient to address
the study question in this, and in the previous paper.2
The use of exhaled nitric oxide levels in clinical practice
has been the focus of numerous studies and considerable
debate. There is an emerging consensus, poised somewhere
between outright enthusiasm and sceptical nihilism, that
the utility of FENO is greatest in identifying the potential (or
not) for steroid responsiveness and in assessing complex
asthma in which there is significant discordance between
the symptoms which the patient is reporting, and the
intensity of underlying airway inflammation. These two
aspects were simultaneously considered in a recent study
of 102 patients with poorly controlled asthma, and the
question was posed: can FENO be used to predict those
patients in whom additional inhaled or oral steroid would or
would not be helpful.23 Interestingly, 49/102 did not gain
control despite maximum doses of inhaled fluticasone and
the addition of oral steroid. FENO values of less than 30 ppb
were associated with predictive values of >90% for the
absence of response to high dose therapy. These results
demonstrate the usefulness of FENO in directing the clini-
cian away from inappropriate treatment.
The interpretation and use of exhaled nitric oxide
measurements in clinical practice has recently been more
fully defined,24,25. However, although the new ATS guideline
refers to the various reference equations which are now
available, it was written in the absence of any reports
regarding the application of reference values in practice.
Thepresent limited report suggests that absolute rather than
predicted values are still to be preferred. However, clearly
further work on this topic is required to confirm this view.Author contribution
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